HomeInvestors HealthFDA clears Insulet's Omnipod 5 for type 2 diabetes (NASDAQ:PODD)

FDA clears Insulet’s Omnipod 5 for type 2 diabetes (NASDAQ:PODD)

August 26, 2024

Insulet (NASDAQ:PODD) said it has received FDA clearance for its Omnipod 5 Automated Insulin Delivery, or AID, system for the treatment of type 2 diabetes in adults.
The company said the clearance makes Omnipod 5 the only AID system approved for both type 1 and type 2 diabetes management.

latest articles